BGCOLOR="#FFFFFF">

I. COMMENCED TRADING IN JANUARY

Company (Symbol)

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

INITIAL OFFERINGS

Biotron Ltd. (Australia)1

N/A

1/24**

N/A

N/A

N/A

N/A

A$12

N/A

Exact Sciences Corp. (EXAS)2

10/27

1/31

4S

$14

18.7

Merrill Lynch (co-lead) CIBC World Markets (co-lead) Thomas Weisel Partners (co-lead) Merrill Lynch International CIBC World Markets plc

$56

$54.8

Total: $62.6M

Number of IPOs in January: 2

Average value of January IPOs: $31.3M

Number of IPOs for 2001: 2

Total raised in IPOs in 2001: $$62.6M

Average value of IPOs in 2001: $31.3M

Notes:

** Denotes the date item ran in BioWorld International.

1 Biotron conducted its IPO in Australia.

2 In Exact's IPO, the U.S. portion of the offering consisting of 3.2M shares is being led by Merrill Lynch & Co., CIBC World Markets Corp. and Thomas Weisel Partners LLC. The international portion of the offering, about 800,000 shares, is being led by Merrill Lynch International, CIBC World Markets plc and Thomas Weisel Partners LLC. U.S. underwriters have an overallotment option for 480,000 shares, while international underwriters have an overallotment option for 120,000 shares.

FOLLOW-ON OFFERINGS

Company (Symbol)

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

Genetronics Biomedical Ltd.3 (AMEX:GEB)

1/18

1/18

6.27S

C$1.35

N/A

Canaccord Capital Corp. (placement agent)

C$8.46 (US$5.59)

N/A

Guilford Pharmaceuticals Inc. (GLFD)4

11/20

1/16

2.656S

$17.50

24

Legg Mason Wood Walker Ladenburg Thalmann & Co. (placement agents)

$46.5

$45.6

Notes:

3 Genetronics conducted its offering in Canada on the Toronto Stock Exchange. Figures include the exercise of a 15% overallotment option

4 Guilford's offering was part of a shelf registration and includes agreements to sell an additional 411,000 shares of its stock to a small number of institutional investors for $7.16M. Legg Mason Wood Walker and Ladenburg, Thalmann & Co. acted as placement agents in connection with the sale of portions of these shares

Total: $52.09M

Number of follow-on offerings in January: 2

Average value of January follow-ons: $26.045M

Number of follow-on offerings in 2001: 2

Total raised in follow-ons in 2001: $52.09M

Average value of follow-ons in 2001: $26.045M

II. FILED AND PENDING

Company (Symbol/Proposed Symbol)*

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

Acadia Pharmaceuticals Inc. (ACAD)1

12/21

5S

$13-15

15.8

Robertson Stephens Inc. U.S. Bancorp Piper Jaffray

$75

Amersham Pharmacia Biotech (APBiotech; APBI)2

10/3

N/A

N/A

N/A

Morgan Stanley Dean Witter (co-lead) Goldman, Sachs & Co. (co-lead) Chase H&Q Salomon Smith Barney

$100

Athersys Inc.3 (ATHX)

10/12

N/A

N/A

N/A

Credit Suisse First Boston Dain Rauscher Wessels ING Barings LLC

$115

BioMedicines Inc.4 (BIOS)

11/3

N/A

N/A

15

UBS Warburg LLC U.S. Bancorp Piper Jaffray Pacific Growth Equities

$57.5

BioTissue Technologies AG5 (Germany)

11/29**

1S

EUR27-34

N/A

Landesbank Baden-Wuerttemberg Equinet Securities AG Direkt Anlage Bank AG

EUR27 (US$23)

CombiMatrix Corp. (CLMX)6

11/22

N/A

N/A

N/A

Salomon Smith Barney (co-lead) J.P. Morgan & Co. (co-lead)

$100

diaDexus Inc.7 (DDXS)

11/20

7S

$12-14

31.1

Lehman Brothers Inc. CIBC World Markets Corp. Prudential Vector Healthcare Fidelity Capital Markets

$91

DoubleTwist Inc.8 (DBLT)

9/1

5S

$13-15

24.2

Lehman Brothers Inc. Dain Rauscher Wessels Thomas Weisel Partners LLC Fidelity Capital Markets

$70

DNA Sciences Inc.9 (DNAS)

1/8

N/A

N/A

N/A

Lehman Brothers Inc. CIBC World Markets Corp. Dain Rauscher Wessels Inc.

$125

Dynavax Technologies Corp. (DVAX)10

12/5

N/A

N/A

N/A

Bank of America Securities LLC UBS Warburg (joint leads)

$75

Genometrix Inc.11 (GNMX)

3/15

7S

$10-12

30.1

Lehman Brothers (co-lead) Chase H&Q (co-lead) Dain Rauscher Wessels Thomas Weisel Partners LLC Fidelity Capital Markets

$77

Hemosol Inc.12 (Canada; TSE:HML)

1/18

7S

C$11.50

32.269

UBS Warburg LLC Dain Rauscher Wessels

C$80.5 (US$53)

Kinetek Pharmaceuticals Inc. (Canada)13

10/20

N/A

N/A

N/A

N/A

N/A

NetGenics Inc. (NTGC)14

3/13

5.5S

$11-13

23.5

Chase H&Q UBS Warburg LLC

$66

Seattle Genetics Inc. (SGEN)15

11/20

N/A

N/A

21.7

J.P. Morgan Securities Inc. CIBC World Markets Corp. Bank of America Securities LLC

$75

Third Wave Technologies (TWTI)16

7/31

8.5S

$11-13

44

Lehman Brothers CIBC World Markets Corp. Robert W. Baird & Co. Fidelity Capital Markets Dain Rauscher Wessels

$102

Xcyte Therapies Inc. (XCYT)17

12/22

N/A

N/A

N/A

S.G. Cowen Securities Corp. (co-lead) U.S. Bancorp Piper Jaffray (co-lead) Dain Rauscher Inc. First Security Van Kasper Inc.

$86.2

FOLLOW-ON OFFERINGS

Aastrom Biosciences Inc. (ASTM)18

12/7

6.35S

$1.27

33.84

N/A

$8.1

Alexion Pharmaceuticals Inc. (ALXN)19

10/6

N/A

N/A

N/A

N/A

$300

AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALRXF)20

11/16

N/A

C$1.90

N/A

HSBC Securities Inc. (co-lead) Roth Capital Partners (co-lead)

C$12 (US$7.8)

AnorMED Inc. (Canada; TSE:AXO; OTC BB:ALXFF)21

1/23

1.5S

C$17

23.9

BMO Nesbitt Burns Inc. Goepel McDermid Inc. RBC Dominion Securities Inc. CIBC World Markets Corp.

C$25.5 (US$16.92)

Aviron Inc. (AVIR)22

12/18

3S

$53.75

22.22

Morgan Stanley Dean Witter J.P. Morgan Chase & Co. S.G. Cowen Securities Corp.

$311.25

CV Therapeutics Inc. (CVTX)23

1/4

N/A

N/A

N/A

N/A

$400

Igen International Inc. (IGEN)24

1/2

3S

$13.20

N/A

N/A

$39.6

Medarex Inc. (MEDX)25

12/22

N/A

N/A

N/A

N/A

$500

NeoTherapeutics Inc. (NEOT)26

1/3

N/A

N/A

N/A

N/A

$50

Praecis Pharmaceuticals Inc. (PRCS)27

1/26

5.5S

$30.875

$41.9

Salomon Smith Barney Credit Suisse First Boston CIBC World Markets Corp.

$170

Regeneron Pharmaceuticals Inc. (REGN)28

1/25

4S

$36.68

36.7

Merrill Lynch & Co. J.P. Morgan Chase & Co. Robertson Stephens Inc.

$146.7

Scios Inc. (SCIO)29

1/19

6.4S

$18.625

38.5

N/A

$120

The Medicines Co. (MDCO)30

1/8

4S

$16.953

29.3

J.P. Morgan & Co. (co-lead) Robertson Stephens Inc. (co-lead) CIBC World Markets Corp. U.S. Bancorp Piper Jaffray

$67.812

Transkaryotic Therapies Inc. (TKTX)31

12/13

N/A

N/A

N/A

N/A

$500

Xoma Ltd. (XOMA)32

11/17

10S

$11.25

N/A

N/A

$112.5

Notes:

* Stock symbols for companies seeking to complete IPOs are proposed. **Denotes the date the item ran in BioWorld International.

1 Acadia's underwriters have an overallotment option for 750,000 shares.

2 APBiotech's IPO is expected to occur in February. No further details were disclosed.

3 Athersys did not disclose any further details.

4 BioMedicines did not disclose any further details.

5 BioTissue's IPO filing is for Frankfurt's Neuer Markt. There is a greenshoe of 117,000 shares available to the underwriters.

6 CombiMatrix did not disclose any further details.

7 DiaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

8 DoubleTwist's IPO value, $70M, is based on the sale of 5M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 750,000 shares.

9 DNA Sciences did not disclose any further details.

10 Dynavax did not disclose any further details.

11 Genometrix's IPO value, $77M, is based on the sale of 7M shares at $11 each, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

12 Hemosol's underwriters have an option to purchase an additional 1.05M shares to cover overallotments. The offering is being conducted in the U.S.

13 Kinetek's proposed IPO was filed in Canada. No further details were disclosed.

14 NetGenics' IPO value, $66M, is based on the sale of 5.5M shares at $12 each, the midpoint of the expected price range. The underwriters have an overallotment option for 825,000 shares.

15 Seattle Genetics did not disclose any further details.

16 Third Wave's underwriters have an overallotment option for 1.275M shares.

17 Xcyte did not disclose any further details.

18 Aastrom's offering value, $8.1M, is based on the proposed maximum aggregate price of $1.27 per share for 6.35M shares.

19 Alexion filed a shelf registration to offer common stock, debt or warrants, up to a value of $300M.

20 AltaRex filed a final prospectus announced Jan. 26. The offering was expected to close Feb. 8.

21 AnorMED's underwriters have an overallotment option for 1.5M shares.

22 Aviron amended its shelf registration 1/12 to publicly offer 3M shares of common stock and $150M aggregate principal convertible subordinated notes. The value of the offering, $311.25 includes the notes and is based on the sale of 3M shares at an assumed price of $53.75, Aviron's opening price on Jan. 12. The underwriters have an overallotment option for an additional 450,000 shares ­ 250,000 from the company and 200,000 from selling shareholders ­ and an additional $22.5M in convertible notes.

23 CV filed a shelf registration to sell up to $400M in debt securities, preferred and common stock and warrants.

24 Igen filed a shelf registration to sell up to 3M shares of its common stock. The price range and value of the shares is based on the Jan. 2 opening price of the company's stock.

25 Medarex filed a shelf registration statement to offer up to $500M of common stock, preferred stock, warrants and debt securities.

26 NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M.

27 The value of Praecis' offering, $170M, is based on the closing stock price of $30.875 on Jan. 25. The underwriters have an overallotment option for an additional 825,000 shares.

28 Regeneron's underwriters have an overallotment option for an additional 600,000 shares. The value of the offering, $146.7M, is based on the closing stock price on Jan. 25.

29 Scios filed to sell 6.4M shares under a shelf registration. The value of the offering, $120M, is based on the Jan. 17 closing stock price of $18.625.

30 The value of The Medicines Co.'s offering, $67.812M, is based on the sale of 4M shares at the Jan. 8 opening stock price of $16.953. The underwriters have an overallotment option for 600,000 shares.

31 Trankaryotic Therapies filed a shelf registration statement for the sale of up to $500M in securities.

32 Xoma filed a shelf registration statement for the sale of up to 10M shares. The value, $112.5M, is based on the Nov. 16 closing price.